US 11,926,659 B2
Antibodies recognizing tau
Tarlochan S. Nijjar, Orinda, CA (US); Robin Barbour, Walnut Creek, CA (US); Philip James Dolan, III, Foster City, CA (US); Yue Liu, Foster City, CA (US); Svetlana Alexander, Sunnyvale, CA (US); and Mark E. Renz, Millbrae, CA (US)
Assigned to Prothena Biosciences Limited, Dublin (IE)
Filed by PROTHENA BIOSCIENCES LIMITED, Dublin (IE)
Filed on Feb. 22, 2021, as Appl. No. 17/181,997.
Application 17/181,997 is a continuation of application No. 16/808,209, filed on Mar. 3, 2020, granted, now 10,961,302.
Claims priority of provisional application 62/838,159, filed on Apr. 24, 2019.
Claims priority of provisional application 62/813,137, filed on Mar. 3, 2019.
Claims priority of provisional application 62/813,126, filed on Mar. 3, 2019.
Prior Publication US 2021/0261652 A1, Aug. 26, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/18 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01); C12N 15/63 (2006.01); G01N 33/68 (2006.01)
CPC C07K 16/18 (2013.01) [C12N 15/63 (2013.01); A61K 9/0019 (2013.01); A61K 45/06 (2013.01); C07K 2317/565 (2013.01)] 32 Claims
OG exemplary drawing
 
1. An isolated antibody specifically binding to human tau, comprising: a mature heavy chain variable region comprising CDR-H1 comprising SEQ ID NO:8, CDR-H2 comprising SEQ ID NO: 9 or SEQ ID NO: 149, and CDR-H3 comprising the amino acid sequence of LDF, wherein the heavy chain variable region is at least 90% identical to SEQ ID NO:18; and a mature light chain variable region comprising CDR-L1 comprising SEQ ID NO: 12, CDR-L2 comprising SEQ ID NO: 150, 151, 153, 156, 158, 159, 160, 163, 165, 166, 167, 168, 169, 170, 171, 172, 173 or 174, and CDR-L3 comprising SEQ ID NO:14, wherein the light chain variable region is at least 90% identical to SEQ ID NO: 122.